In the context of the COVID-19 pandemic, it is of the utmost importance to accelerate the discovery and development of safe and more effective drugs and vaccines. Therefore we offer companies, research institutions and clinics an exchange platform for the search for partners, technologies and expertise in the context of COVID-19 research projects.
-> To the projects of the BioM-COVID-19 platform.
a) We publish here your inquiry or offer.
b) If the project is to be treated confidentially, we will be happy to take your suggestions and connect you with suitable partners from the academic or industrial sectors.
We would also like to draw your attention to the following additional contact points:
Forum Medtech Pharma
Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit (LGL)
BIO.NRW COVID-19 Information- and Contact-Platform
BIOWIN Wallonia Platform
4G Clinical is offering global RTSM / IRT / IxRS / IWR services to bringing crucial medicines to those who need them, faster.
Climedo Health offers its web-based platform for clinical data collection including digital patient diaries free of charge for medical practices, clinics, research institutes and non-profit organizations doing research related to COVID-19 (Coronavirus) / SARS-CoV-2. Climedo’s predefined digital eDiaries and ePROs (“electronic Patient Reported Outcomes”) will allow test subjects to submit potential symptoms, side effects or information on their state of wellbeing remotely via a mobile device or computer, even while being quarantined.
Support regarding CE marking of medical devices and IVD medical devices:
We offer to consult you 15 min free of charge, how to assess sensitivity in a fast approach and how to place your product on the market under "emergency use authorization".
Tag your message with @IVD and you will be forwarded to the IVD team by our dispatchers.
Offer: Rapid clinical trial setup and statistical consulting - biostatistical services – clinical data management.
We are ready for rapid & high quality support of COVID-19 studies: Statistical consulting, eCRF setup & clinical data management. We’ll donate all fees from statistical consulting for COVID-19 studies to the University Hospital in Essen (https://spenden-für-corona.de) - our contribution to the Corona fight.
Profil is stepping up to this responsibility by offering support to companies developing vaccines against COVID-19. As one of the leading phase 1 units in Europe, we can offer experience with Europe's regulatory landscape as well as years of routine in conducting early phase trials in our two clinics in Germany. Combined with our team's previous experience working on novel vaccine developments this allows us to support companies looking for rapid and effective support in their clinical development.
Proinnovera is available to manage clinical research projects related to COVID-19. We have over 20 years of experience in providing the following services in various therapeutic areas including vaccination studies:
The Biomax Offering in the field of COVID-19 research activities consists of three parts:
Building up a human Coronavirus Disease Map to support SARS-CoV-2 pathobiology research and vaccine development by combining literature mining with expert curation and semantic data integration.
Providing a knowledge management solution for integration of clinical, laboratory, imaging and high-throughput experimental data with prior knowledge from structured databases and literature mining.
We currently seek partners either interested in contributing SARS-CoV-2 specific data or looking for integrated data and knowledge resources for integrative analysis and machine learning.
We offer research projects the possibility to use our database software for clinical studies and database development.
We can also support projects with our knowledge in software development and big data analysis. Depending on the application a prototype can be provided by us within a few days free of charge.
1. Online Image Annotation Tool for free
2. Develop computer vision AI
MDs, researchers, medical labs, clinics, scientists, data engineers – if you need an image annotation tool to fight #coronavirus and label e.g. x-ray images, then we offer our platform www.datagym.ai for FREE.
We also offer to develop computer vision AI for diagnostic purposes for FREE if you can provide images.
We are looking for partners from pharm industry for drug development and medical partners from university/hospital for diagnosis and research. COVAI-1 is a software infrastructure, an autonomous AI system for diagnostics, prevention, information, detection system and drug research against corona virus. This system supports medical experts by decision making. It creats reproducible and objective results and gives to medical experts the possibility to train their own AI without programming knowledge and is able to train and volidate themself by adding new information. It runs in a cloud by using low power laptops or secured in a lab at a workstation or at an internal infrastructure of it.
We offer a team of data scientists with expertise in biomedical field (bioinformatics, image processing, biostatstics, and machine learning and statistics in general).
In our research group, we have extensive experience in high-throughput data analysis, in particular for sequencing and network data. A main research focus is the development of bioinformatics methods for transcriptomic analysis of virus-infected cells.
We can offer support for:
Contact: Prof. Dr. Caroline Friedel, Research Group Leader, caroline.friedel@, bio.ifi.lmu.dewww.bio.ifi.lmu.de/mitarbeiter/caroline-friedel/forschungsgruppe/index.html
We are looking for partners, and offering technology and capacities of computing power.
We are a Joint Venture of cloud computing providers and data centers which want to provide our combined computing power to biotechs, universities, scientists etc. which are fighting corona.
Gesucht: für CoV2-ELISA Expressionsplasmid für die RBD (receptor binding domain) des CoV2-Spikeproteins und/oder für das CoV2-Nukleokapsid-(N)-Protein, um baldmöglich eine größere eukaryontische Expression beginnen zu können. Am liebsten direkt für FlipIn-CHO-Zellen geeignetes Plasmid, vorzugsweise kloniert mit StrepTag für die Aufreinigung, nehmen aber gerne auch andere Varianten. Noch besser wäre direkt Expressions-Zelllinien für RBD (receptor binding domain) des CoV2-Spikeproteins und/oder für das CoV2-Nukleokapsid-(N)-Protein, die wir in Kultur weiter propagieren dürften. Alternativ auch die gereinigten Proteine.
We are able to quickly (0-2 days) deliver (sell or rent or provide for free during the crysis period) a refurbished ABI 7300 or 7500 or 7500-Fast Real Time PCR device from our stock to labs, who want to increase their Corona test capacity
We are offering our technological and bioinformatic expertise for the development of comprehensive IT platforms, for handling and analyzing biomedical data gained through COVID-19 testing. We already have a partner for the laboratory preparation of samples. The laboratory equipment is currently expanded to scale-up the workflow.
We are an international distributor with a global partner network. We can provide more than 20 Million products of more than 140 partner companies around the world. We now offer CE IVD certified COVID-19 detection kits for diagnostics.
We are sponsoring a small pilot study, looking for a clinical partner that can quickly address and run the clinical study. We will provide the home anti-body testing, and IT platform for analysis.
Microcoat offers the analysis of infectious disease relevant biomarkers, e.g. cytokines on various platforms. We have multiplex panels established on ELLA, MSD and Quanterix platforms.
We have established the Simple Plex COVID-19 Cytokine Storm Panel suitable for measurement of key inflammation markers that are indicative of pathologic inflammatory response.
Benchmark and selection of platforms for the evaluation of new potential biomarkers in early phase and pre-clinical development.
Routine analysis of validated biomarkers in clinical phase (GCP).
We are offering expertise in development and manufacturing of ELISA as well as Lateral Flow Assays.
Microcoat is available for cooperation projects for developing diagnostic assays. Based on established technologies and material platforms we offer rapid development with subsequent large-scale manufacturing capabilities (Bulk materials, ELISA and Lateral Flow Tests).
Contact: Dr. Mark-Steven Steiner; Dr. Harald Waltenberger, Director Diagnostic Raw Materials; Director Development, m.steiner@; microcoat.deh.waltenberger@, Tel: +49-8158 9981 32, microcoat.dewww.microcoat.de
We offer advanced technology for digital mass screening. With its digital healthcare platform myoncare, ONCARE GmbH provides a technical solution for mass screenings. Using a generic QR code, users can register anonymously in the app and complete the screening questionnaire stored there. Based on the score determined from the questions, recommendations for action are automatically made to the user in cooperation with doctors.
Plazus Technologies is a development service provider that also developed a product that is a dedicated communication app for private groups to communicate. Everyone involved in the group, to securely share private information about individuals using blockchain technology.
We would like to extend our protocol and provide the ability to give secure and accurate information and up to date on someone's health history and status.
We offer production capacities for the mass production of lateral flow tests.
We`re looking for partners to develop corona-virus piont of care rapid tests.
We are experts in detecting analytes in saliva or sputum.
We are experts in saliva/ blood/plasma sample preparation for lateral flow tests.
We offer a state-of-the-art handheld device for the electronic readout of lateral flow tests.
We have and offer our know-how and experince of 25 years in developing and producing lateral flow tests.
We are supporting diagnostic manufacturers to get their COVID-19 tests on the market soon according to the EU In Vitro Diagnostic Directive, the new EU In Vitro Diagnostic Regulation and US-FDA regulations.
We are developer and producer of industrial, medical and laboratory equipment according to customers orders. So we are certified according to DIN EN ISO 13485: 2016 and DIN EN ISO 9001:2015. We have special experience with sensors, electronic processing and actuators, as well as with the user interface. Our thinking is interdisciplinary and we take care of everything, as well as the device approval. We are happy to offer our services in the area of development and production of components and devices.
We offer our capacities and experience:
Manufacturing of complex turned and/or milled medical parts made of different materials (according to DIN ISO 9001:2015).
Offering expertise in the field of product development:
We offer technical support backing up your core business development.
We are offering:
• deepwell plates
• microtiter plates
• conductive robotic pipet tips
• transparent robotic pipet tips
• racked microtubes
• dispenser tips
Do you need manufacturing solutions or more capacity for your medical products? Do you need manufacturing according to the specific regulations like ISO13485 or FDA?
Zollner has been providing manufacturing solutions of complex systems to the medical industry for more than 25 years.
Offer: IF experts APPROVE above question - bionic surfaces – is in a position to arrange surface modification of non woven fabrics with potential antiviral compounds like tetrahydrozoline, chlorothiazide chloroquine and formoterol as e.g. pointed out in Pharmacoinformatics and molecular dynamic simulation studies reveal potential inhibitors of SARS-CoV-2 main protease 3CLpro; MA Alamri, MT ul Qamar, SM Alqahtani - 2020 – preprints.org
Partners having lab infrastructure (S3 lab) and personnel to perform tests with SARS CoV 2
Partners having access to active SARS CoV 2 viruses for experiments
Expertise on quantification of viruses on surfaces.
Hardware (UV-C incl. circuitry and UV spectrometers) for irradiating samples and measuring UV light intensity.
Based on the literature other corona viruses like MERS-CoV and SARS-CoV can be successfully inactivated using UV C alone.
UV C disinfection of surfaces with potential SARS CoV 2 viruses has and is been applied already during the current crisis. However, to our knowledge, no quantitative evaluation has been reported in the literature. We propose to determine empirically the dose/inactivation curve for SARS CoV 2 for different UV-C wavelengths. Thus we expect to deduct doses that are effective for the disinfection of surfaces inside hospitals, in public transportation, elevators, etc.
Contact: Dr. Thomas Wendler, CEO, thomas.wendler@, Tel: +49 (176) 82179775 scinthealth.com
We at RAS AG developed an antimicrobial agent based on nanosilver over 15 years ago, which is now sold for various applications and is marketable compliant with the EU Biocide Regulation.
The nanosilver active substance exhibits antiviral efficacy:
Our nanosilver based formulations recently have been tested efficient against different members of the family Coronaviridae.
RAS AG offers technologies to create coatings on various substrates, that contain the antiviral substance. The active substance can be incorporated into materials for long lasting effects.
We are searching for Virologists or laboratory that have experience in the evaluating the efficacy of antiviral substances or surfaces that incorporate those substances. We are developing new products and treated articles, which include antiviral substances. The tests have to be performed with SARS-CoV-2. As result the efficacy has to be quantified at best in a certain percentage of inhibition or log-step reduction of the viral vitality/infectivity. There are different test methods available, we are open to discuss.
2bind has a broad portfolio of different biophysical analytical tools to study drug – target interactions. The range of assay cover biophysical HIT ID (HTS) via HIT validation to characterization of HITs.
Potential hits for COVID19 relevant targets could be identified and validated using different biophysical methods (MST, nanoDSF, ITC, BLI).
We are an international distributor with a global partner network. We can provide more than 20 Million products of more than 140 partner companies around the world. We are working under high pressure to continously update our webshop with products specifically for research and diagnostics on SARS-CoV-2 and COVID-19.
Cellassays GmbH offers label-free tests for efficacy of antiviral substances toward cellular models with microphysiometry.
Looking for partners:
We have coupled a 785nm Raman excitation laser into an inverted digital microscope for fast and easy single cell analysis without any labelling or staining. Due to the unique laser coupling optical trapping features are induced simultaneously that attract cells/bacteria/exosomes/viruses and hold them in position during Raman spectra acquisition. Optional fluorescence modules allow comparison with routine staining procedures.
EpiQMAx offers the analysis of antibodies and small molecules by means of mass spectrometry. In particular, we can characterize biological and biophysical parameters very precisely. Thereby, we support all research activities for COVID19 and offer our platform technology for drug discovery purposes.
What can we offer:
What are we looking for:
Contact: Dr Stefan Jungbluth / Dr Nicola Viebig, Head of Business Development / Chief Scientific Officer, stefan.jungbluth@ / euvaccine.eunicola.viebig@, Tel: +49-176-31615202 / +49-176-31615203, euvaccine.euwww.euvaccine.eu
We are offering a label-free, impedance-based platform to monitor the host cell response in assays addressing the neutralizing capacity of antibodies against Covid-19.
Contact: Prof. Dr. Joachim Wegener, Joachim.Wegener@, Tel: +49-941-943-4546 or +49-179-4872144, emft.fraunhofer.dewww.emft.fraunhofer.de/de/kompetenzen/innovative-sensorloesungen/zell-basierte-sensorik.html, www.ibmt.fraunhofer.de/de/ibmt-kernkompetenzen/ibmt-medizinische-biotechnologie/ibmt-bioprozesse-bioanalytik.html
We can apply recombinant murine gammaherpesvirus 68 (MHV-68) as a challenge virus in mice to test the efficacy of heterologous candidate human vaccines.
Contact: Prof. Dr. Heiko Adler, Deputy Head of Research Unit, Research Group Leader, h.adler@, Tel: +49-89-3187-1327, helmholtz-muenchen.dewww.helmholtz-muenchen.de/lrr/forschung/adler-lab/scientific-focus
We are offering our technology for vaccine development, viral investigations and pathogen-target cell characterization.
We are looking for partners to develop further established methods and who are in the preclinical in vitro testing of vaccine candidates.
Particular for any type of linker technology between biomolecules, antibodies, proteins etc., and small molecules. Linker can be designed that they are stable in all physiological environments or stable in plasma and fragmentize in lysosome.
Offering: Liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis of different antiviral agents and other small molecule compounds from human serum or plasma.
Therapeutic Drug Monitoring of antiviral substances for treatment of COVID-19 patients may be important in clinical studies and may offer therapeutic advantages in standard clinical care. For this purpose, quantification methods will be developed according to the following substance prioritization list:
1. Camostat mesylate, 2. Remdesivir, 3. Favipiravir, 4. Chloroquine/ Hydroxychloroquine, 5. Arbidol, 6. Ritonavir/ Lopinavir, 7. Ribavirin/ Sofosbuvir
Beyond these drug target analytes, the available technical platform could be used to quantify small molecule compounds with potential added diagnostic value in the context of severe viral infections.
Contact: Prof. Dr. med. Daniel Teupser, Director, Institute for Laboratory Medicine, Daniel.Teupser@, Tel: + 49 89 4400 - 73210, med.uni-muenchen.dewww.klinikum.uni-muenchen.de/Institut-fuer-Laboratoriumsmedizin/de/
we are a virology/molecular biology lab working on Coronaviruses for ~15 years
1) Motivated students in bioscience field with benchwork experience (molecular biology, cell culture) for internships, bachelor, masters, PhD work
2) Computer-aided drug design modellors for inhibitor modelling of our most promising coronavirus-host protein-protein interactions
3) Organic chemistry synthesis of small cyclic peptides
Contact: Dr. Albrecht von Brunn, Research group leader, vonbrunn@, Tel: +49-89-218072839, mvp.lmu.dehttp://www.mvp.uni-muenchen.de/forschung/virology/research-group-von-brunn/
We offer easy to use biophysical technologies with low sample consumption and high throughput.
Monolith & Dianthus instruments to measure the binding & affinity of molecules to viruses (dose-response) and molecular targets (interaction studies).
OmicScouts combines cell biology, biochemical and mass spectrometry-based proteomics expertise, computational biology capabilities and drug discovery experience to support drug discovery projects fast and efficient.
Expertise: cell culture media development; sourcing biochemical compounds; manufacture sterile products in industrial scale under ISO 9001 and 13485 standards.
Capacity: 10 000 L sterile filtration per week
We are looking for:
Offering profound expertise and technology for protein related vaccine and drug development;
Looking for partners in related vaccine and drug discovery development or research
QconCAT polypeptides are valuable tools for vaccine and virus research (see below). Apply QconCAT polypeptides in targeted proteomics for SARS-Cov-2/COVID-19 experiments using Q-peptides (unique proteotypic peptides) for quantification by mass spectrometry.
Custom COVID-19 protein expression or expression of protein fragments for SARS-Cov-2 (e.g. SPIKE, ORF3a, Envelope protein, Membrane glycoprotein, ORF8, Nucleocapsid phosphoprotein) or host receptors (e.g. ACE2_HUMAN)
LC-MS calibration kits to standardize workflows between experiments and across different laboratories.
Design and expression of a QconCAT protein to validate Hi3 protein quantification of influenza vaccine antigens. Smith D. et al., J Proteomics. 2016 Sep 2;146:133-40
Sciomics supports COVID-19 research with a focus on:
All assays can be complemented by a SARS-COV-2 proteome wide peptide array.
Offering consumables: Synthetic DNA / RNA products (genes, fragments, oligo pools, libraries) and NGS target capture kits.
Fully synthetic RNA positive controls for SARS-COV-2 (full genome)
SARS-COV-2 NGS Target Enrichment kits
High Throughput DNA Synthesis (DNA fragments, genes, cloned genes)
Oligo Pools, DNA Variant Libraries
Link to our COVID-19 research tools: www.twistbioscience.com/coronavirus-research-tools
Contact: Oliver Latz, NGS Sales specialist, email@example.com, Tel: 49-(0)162-526-843-0, https://www.twistbioscience.com
We can offer to test compounds in cell culture for toxicity and for suppression of COVID19. We are looking for partners who have components, such as new polymerase or protease inhibitors, which have not been tested so far. We have established screening for antiviral compounds in different cell culture models. In addition, we have access to a P3/S3 facility and have already obtained permission to work with wild-type COVID-19.
Contact: Prof. Dr. Jochen Bodem / Dr. Maria Steinke, AG-Leiter, Jochen.Bodem@, Tel: +49-931-3181509, vim.uni-wuerzburg.dewww.virologie.uni-wuerzburg.de/virologie/ags-virologie/ag-bodem/arbeitsgebiete/a-anti-viral-drugs/
We are urgently looking for people who could provide:
- lymphocytes or whole blood samples from people who have been tested CoV-2 positive.
- customized synthetic peptides, length approximately 15 peptides. About 1 mg, do NOT need to be high-purified.
- fast (48 hours) HLA typing for about 5 samples, only A B C classification required
Contact: Dr. Ramona Krauss, Study Coordinator, Ramona.Krauss@med.uni-muenchen.de, Tel: +49 89 4400 52990
We offer already a well-received Multiplex Real-time PCR assay ampliCube Coronavirus Panel. In addition, we are currently developing tests for the serological antibody detection of SARS-CoV-2. This will be both a screening test in our recomWell format (ELISA platform) and a confirmation test based on a strip test (recomLine).
We would need blood samples from SARS-CoV-2 patients and also serological patient samples for SARS-1 as well as seasonal corona viruses for differentiation.
approved oral drug formulation and injectable study drug formulations for clinical trials and in vitro studies.
Request: Partners for clinical studies
Eventually: partners providing anti-viral drugs
We are looking for pharmaceutical companies or investors which have the ability to speed up the development of our new drug (currently R&D substance) against the SARS class of compounds of course as well against COVID-19 and a number of other viruses (i.e. Zika).
We are looking for partners for pre-clinical validation of the antibodies as well as for large-scale production (ideally, GMP compliant)
We offer a medical device for the significant reduction of bacteria and viruses in the upper respiratory tract at mechanically ventilated patients.
We are looking for lab-capacities and (pre-) clinical partners to evaluate the efficacy of cold plasma against SARS-CoV-2 in-vitro. Further we are looking for clinical partners for in-vivo testing and evaluation of SARS-CoV-2 reduction and prevention of super-infections.
Vivoryon Therapeutics offers our small molecule compounds for testing of efficacy against corona virus.
We are looking for a partner with capability of testing small molecules in a disease relevant context.
CEVEC offers the CAP® cell line for COVID-19 vaccine development and production. The human suspension cell line (and derivatives thereof) has been proven in a variety of applications as a superior production cell line for vaccines, both complex peptides/ proteins as well as viral vaccines. It is particularly well suited for production of vaccines based on Adenoviral vectors, as it avoids RCA formation.